Hugo Ribeiro: Which NSAIDs Are Safest for Older Adults?
Hugo Ribeiro, Invited Specialist of Palliative Medicine at European Commission, shared a post on LinkedIn:
“I am delighted to announce that our article ‘Appropriate Prescription of Non-Steroidal Anti-Inflammatory Drugs in Geriatric Patients—A Systematic Review’, published in BioChem, was selected as an Editor’s Choice article.
This recognition highlights our work as one of the most significant and high-quality articles published in this journal.
This systematic review of 39 studies (patients more than 65 years) compares the safety of ibuprofen, naproxen, acemetacin, diclofenac, celecoxib, and etoricoxib.
Celecoxib has a more favorable GI, renal and CV safety profile versus the other studied NSAIDs. Acemetacin shows a promising greater safety profile but remains unproven and requires dedicated research.
Diclofenac and etoricoxib are linked to higher cardiovascular risk. Evidence is limited by heterogeneity and scarce geriatric-specific data overall.
Congratulations to all authors, specially to Dr. Carolina Costa! Prof. Andrade Jose Paulo, Dr. Diana Soares, Dr. Ana Borges and Dr. Ana Gonçalves.”
Stay updated with Hemostasis Today.
-
Aug 25, 2026, 19:45Cara T. Hoepner: Omega-3 is Not an Exposure
-
Aug 25, 2026, 19:42Mark Skinner Honored With the Lifetime Achievement Award – National Bleeding Disorders Foundation
-
Aug 25, 2026, 19:41Katrina Snow: Honoured to Share NYG’s Ongoing QI Work Focused on Transfusion Safety in SCD
-
Aug 25, 2026, 19:39José María López Alemany: Madrid Makes an Urgent Appeal for Blood Donation as Reserves Fall to 38%
-
Aug 25, 2026, 19:36Carlos Mirel Peñate: How Are We Actually Managing AF in ATTR-CM?
-
Aug 25, 2026, 19:35Kelly Anderson: Anticoagulation and Cognitive Health in Older Adults With AF and Alzheimer’s Disease
-
Aug 25, 2026, 19:34Uriel Suárez: Managing Anticoagulation in Patients With Brain Metastases
-
Aug 25, 2026, 19:33Ali Moradi: Excited to Present Two Abstracts at AHA 2026
-
Aug 25, 2026, 19:31Sidi Mohamed El Amine Benlazar: How Romiplostim Induces Immune Tolerance in the Treatment of ITP